The future of targeted therapeutics in oncology: Targets to find, early and long term treatments;Le futur des thérapeutiques ciblées en oncologie: Trouver les cibles, traiter tôt et au long cours

Medecine/Sciences

Volumn 23, Issue 12, 2007, Pages 1073-1074

  Blay, Jean Yves ^a,b,c,d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d Conticanet Network of Excellence ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; RITUXIMAB; TRASTUZUMAB;

CANCER SURVIVAL; CANCER THERAPY; DISEASE COURSE; DRUG EFFICACY; EARLY INTERVENTION; EDITORIAL; GENE AMPLIFICATION; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LONG TERM CARE; ONCOLOGY; PROGNOSIS; TUMOR GROWTH;

EID: 37849049979     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200723121073     Document Type: Editorial

References (13)

1. Druker BJ, Talpaz M, Resta OJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 ; 344 : 1084-6.
2. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial. Lancet 2004 ; 364 : 1127-34.
3. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004 ; 31(suppl 6) : 30-6.
4. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year : the French Sarcoma Group. J Clin Oncol 2007 ; 25 : 1107-13.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ; 350 : 2335-42.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.
7. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for mstatic breast cancer that overexpresses HER2. N Engl J Med 2001 ; 344 : 783-92.
8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960-4.
9. Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004 ; 114 : 379-88.
10. Charafe-Jauffret E, Chaffanet M, Bertucci F, et al. Les cancers du sein : vers un modèle cellulaire et moléculaire intégré. Med Sci (Paris) 2007 ; 23 : 626-32.
11. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006 ; 42 : 1093-103.
12. Romond EH, Perez EA, Bryant J, et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1673-84.
13. Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer : a randomised controlled trial. Lancet 2007 ; 369 : 29-36.